首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

市場調查報告書

商品編碼

1628131

癌症診斷市場機會、成長動力、產業趨勢分析與預測 2025 - 2034

Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2024年11月22日 | 出版商:

Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球癌症診斷市場到 2024 年價值為 1587 億美元，預計 2025 年至 2034 年間將以 9% 的複合年成長率穩定成長。主要目的是確定癌症的類型、位置和進展，以便及時有效的治療，從而改善患者的治療結果。

市場擴張主要是由全球癌症盛行率不斷上升所推動的。預測顯示癌症病例數量急劇增加，強調了對先進診斷方法的迫切需求。這種日益增加的負擔正在推動成像和分子診斷等技術的採用，這些技術在早期檢測和準確診斷中發揮著至關重要的作用。

醫療保健系統的技術進步，特別是在發展中地區，正在進一步推動市場成長。對醫療保健基礎設施的投資和包括遠距醫療在內的尖端工具的引入，使癌症診斷變得更加容易和高效。這些創新支持更快、更精確的檢測，改善整體患者護理。

市場範圍
開始年份	2024年
預測年份	2025-2034
起始值	1,587 億美元
預測值	3,725 億美元
複合年成長率	9%

市場按應用細分為腫瘤生物標記測試、影像、活體組織切片、液體活體組織切片、免疫組織化學和原位雜合技術。影像佔據最大的收入佔有率，到 2024 年將佔 63.6%。

根據癌症類型，市場分為幾個部分，包括膀胱癌、乳腺癌、大腸癌、子宮內膜癌、腎癌、肝癌、肺癌和前列腺癌。 2024 年，肝癌和肺癌合計佔市場佔有率的 18.4%，預計到 2034 年將出現強勁成長。環境觸發因素和不健康的生活習慣等因素正在推動這些癌症的發病率增加，凸顯了有效診斷的迫切需要解決方案。

最終用戶部分包括醫院、診斷實驗室、影像中心和癌症研究機構。醫院由於廣泛採用先進的診斷設備和熟練的醫療保健專業人員而在這一類別中佔據主導地位。有利的報銷政策進一步支持細分市場的成長，確保獲得高品質的診斷服務。

從地區來看，美國預計將經歷顯著的市場擴張，預計到 2034 年市場規模將達到 1350 億美元。

產業生態系統分析
產業影響力
- 成長動力
  - 全球癌症盛行率上升
  - 政府和其他組織為傳播疾病意識而採取的多項舉措
  - 發展中國家的診斷實驗室數量不斷增加
  - 已開發國家的技術進步
- 產業陷阱與挑戰
  - 高資本投資以及與診斷影像系統相關的高成本
  - 與影響 CT 掃描儀使用的高輻射暴露相關的風險
成長潛力分析
監管環境
技術景觀
- 核心技術
- 鄰近技術
未來市場趨勢
差距分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按應用分類，2021 - 2034 年

主要趨勢
腫瘤生物標記測試
影像學
- 超音波和放射學
- 乳房X光檢查
- 核磁共振掃描
- 正子斷層掃描
- CT掃描
- SPECT 和其他影像
活體組織切片
液體活體組織切片
免疫組織化學
原位雜合技術

第 6 章：市場估計與預測：按癌症類型，2021 - 2034 年

主要趨勢
膀胱癌
乳癌
結腸癌和直腸癌
子宮內膜癌
腎癌
白血病
肝癌和肺癌
黑色素瘤
非何杰金氏淋巴瘤
胰腺癌
攝護腺癌
甲狀腺癌
其他癌症類型

第 7 章：市場估計與預測：按最終用途，2021 - 2034 年

主要趨勢
醫院
診斷實驗室
診斷影像中心
癌症研究機構

第 8 章：市場估計與預測：按地區，2021 - 2034

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 俄羅斯
亞太地區
- 中國
- 日本
- 印度
- 澳洲
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第 9 章：公司簡介

Abbott Laboratories
AB Sciex Pte
Agilent Technologies
Becton, Dickinson and Company
Biocare Medical
Biocartis
Biomerieux
Bio-Rad Laboratories
Danaher Corporation
F-Hoffmann-La Roche
GE Healthcare
Hologic
Johnson & Johnson
Koninklijke Philips
Myriad Genetics
QIAGEN
Siemens Healthineers
Sysmex Corporation
Thermo Fisher Scientific

簡介目錄

Product Code: 2406

The Global Cancer Diagnostics Market, valued at USD 158.7 billion in 2024, is poised for steady growth at a CAGR of 9% between 2025 and 2034. Cancer diagnostics encompasses a range of tests and technologies designed to detect and identify cancer at its earliest stages. The primary aim is to determine the type, location, and progression of cancer to enable timely and effective treatment, thereby improving patient outcomes.

The market expansion is primarily driven by the increasing global prevalence of cancer. Projections indicate a sharp rise in the number of cancer cases, emphasizing the critical need for advanced diagnostic methods. This growing burden is boosting the adoption of technologies such as imaging and molecular diagnostics, which play a crucial role in early detection and accurate diagnosis.

Technological advancements in healthcare systems, particularly in developing regions, are further propelling market growth. Investments in healthcare infrastructure and the introduction of cutting-edge tools, including telemedicine, have made cancer diagnostics more accessible and efficient. These innovations support faster and more precise detection, improving overall patient care.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$158.7 Billion
Forecast Value	$372.5 Billion
CAGR	9%

The market is segmented by application into tumor biomarker tests, imaging, biopsy, liquid biopsy, immunohistochemistry, and in situ hybridization. Imaging accounts for the largest revenue share, capturing 63.6% in 2024. Increasing awareness about breast cancer screenings and developing advanced imaging technologies are key contributors to this segment's dominance.

By cancer type, the market is categorized into several segments, including bladder, breast, colorectal, endometrial, kidney, liver, lung, and prostate cancer. Liver and lung cancers together accounted for 18.4% of the market share in 2024 and are expected to see robust growth through 2034. Factors such as environmental triggers and unhealthy lifestyle habits are driving the increased incidence of these cancers, highlighting the urgent need for effective diagnostic solutions.

End-user segments include hospitals, diagnostic laboratories, imaging centers, and cancer research institutes. Hospitals dominate this category due to their widespread adoption of advanced diagnostic equipment and the presence of skilled healthcare professionals. Favorable reimbursement policies further support segment growth, ensuring access to high-quality diagnostic services.

Regionally, the U.S. is expected to experience significant market expansion, with projections estimating the market size to reach USD 135 billion by 2034. Factors like an aging population and increased demand for advanced diagnostic tools contribute to the growth in this region.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of cancer globally
  - 3.2.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
  - 3.2.1.3 Growing number of diagnostic laboratories in developing countries
  - 3.2.1.4 Technology advancements in developed countries
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High capital investment coupled with high costs associated with diagnostic imaging systems
  - 3.2.2.2 Risk related with high radiation exposure affecting use of CT scanner
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Gap analysis
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

5.1 Key trends
5.2 Tumor biomarkers tests
5.3 Imaging
- 5.3.1 Ultrasound and radiology
- 5.3.2 Mammography
- 5.3.3 MRI scan
- 5.3.4 PET scan
- 5.3.5 CT scan
- 5.3.6 SPECT and other imaging
5.4 Biopsy
5.5 Liquid biopsy
5.6 Immunohistochemistry
5.7 In situ hybridization

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2034 ($ Mn)

6.1 Key trends
6.2 Bladder cancer
6.3 Breast cancer
6.4 Colon and rectal cancer
6.5 Endometrial cancer
6.6 Kidney cancer
6.7 Leukemia
6.8 Liver and lung cancer
6.9 Melanoma
6.10 Non-hodgkin lymphoma
6.11 Pancreatic cancer
6.12 Prostate cancer
6.13 Thyroid cancer
6.14 Other cancer types

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Diagnostic laboratories
7.4 Diagnostic imaging centers
7.5 Cancer research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Russia
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE